Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Faster Effects, Vivus Hopes For Quicker Market Penetration For ED Drug Stendra

This article was originally published in The Pink Sheet Daily

Executive Summary

Dosing instructions to take Stendra (avanafil) 30 minutes before sexual activity give the Vivus drug a shot at the crowded marketplace. With the potential approval of the obesity therapy Qnexa coming up, Vivus could be an attractive take-over target.

You may also be interested in...



Stendra Gets Its 15 Minutes, With New FDA-Approved ED Claim

Auxilium’s erectile dysfunction drug avanafil was approved by FDA for its ability to work after 15 minutes, a new claim that Auxilium expects will help to differentiate Stendra in a competitive market.

Deals Of The Week: Value Surprise!

Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen

Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz

Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel